(Q41945144)

14 October 2017

Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients (English)

1 reference

systemic lupus erythematosus

14 October 2017

0 references

1 reference

based on heuristic

inferred from title

author

Anna Sysa-Jedrzejowska

5

object named as

A Sysa-Jedrzejowska

1 reference

14 October 2017

A Wozniacka

1

1 reference

14 October 2017

A Lesiak

2

1 reference

14 October 2017

J Narbutt

3

1 reference

14 October 2017

D P McCauliffe

4

1 reference

14 October 2017

1 January 2006

1 reference

14 October 2017

1 reference

14 October 2017

15

1 reference

14 October 2017

5

1 reference

14 October 2017

268-275

1 reference

Concepts of pathogenesis of systemic lupus erythematosus

14 October 2017

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Cytokine abnormalities in human lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Role of interleukin 15 and interleukin 18 in inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Dosage of Antimalarial Drugs for Children with Juvenile Rheumatoid Arthritis and Systemic Lupus Erythematosus: A Clinical Study with Determination of Serum Concentrations of Chloroquine and Hydroxychloroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Chloroquine stabilization of phospholipid membranes against diacylglycerol-induced perturbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Immunosuppressive potential of antimalarials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Antimalarials--the 'real' advance in lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

The role of cytokines in the immunopathogenesis of lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Rationale for interleukin-6 blockade in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Anti-cytokine therapy in systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

IL-18 cDNA vaccination protects mice from spontaneous lupus-like autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

An endotoxin-induced serum factor that causes necrosis of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Human keratinocytes are a source for tumor necrosis factor alpha: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

SLE - Complex cytokine effects in a complex autoimmune disease: tumor necrosis factor in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Antimalarial drugs inhibit phospholipase A2 activation and induction of interleukin 1beta and tumor necrosis factor alpha in macrophages: implications for their mode of action in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Role of biological agents in immune-mediated inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Production of intracellular and extracellular interleukin-1 alpha and interleukin-1 beta by peripheral blood monocytes from patients with connective tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203306LU2299OA

10.1191/0961203306LU2299OA

21 January 2018

Identifiers

DOI

1 reference

14 October 2017

1 reference